NHU(002001)2025-04-29 10:52Financial Performance - In 2024, the company achieved a revenue of CNY 21,609,592,228.45, representing a year-on-year growth of 42.95% [2] - The net profit attributable to shareholders was CNY 5,868,545,988.62, with a year-on-year increase of 117.01% [2] - In Q1 2025, the revenue reached CNY 5,439,577,817.97, showing a growth of 20.91% [2] - The net profit attributable to shareholders for Q1 2025 was CNY 1,879,910,462.58, reflecting a growth of 116.18% [2] Project Updates - The solid methionine project (70,000 tons) is still in the approval and construction phase [3] - The energy-saving review for the methionine project has not passed, but it does not affect the existing production and sales [3] - The liquid methionine project in partnership with Sinopec is currently in the trial production preparation stage [3] - The company has new material product plans in Zhejiang, Shandong, and Tianjin [3] Strategic Initiatives - The company is focused on the fine chemical industry, leveraging "Chemistry+" and "Biology+" as core technology platforms [4] - Future growth drivers include integrated, series, and collaborative development strategies, emphasizing innovation and the development of functional chemicals [4] - The company plans to continue its ESG initiatives, implementing sustainable development strategies and focusing on creating more value for society [4] - A share buyback plan of CNY 300 million to 600 million is set to enhance shareholder returns and boost market confidence [3]